The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.
S. Hegewisch-Becker
Consultant or Advisory Role - Merck; Roche
C. A. Lerchenmuller
No relevant relationships to disclose
A. Welt
Consultant or Advisory Role - Amgen; AstraZeneca; Essex Pharma; Fresenius Biotech
Honoraria - Pfizer; Pierre Fabre Medicament; Roche
T. Decker
No relevant relationships to disclose
M. Just
No relevant relationships to disclose
C. Steffens
No relevant relationships to disclose
A. Hipper
No relevant relationships to disclose
N. Marschner
Honoraria - Roche